GLPwatch
Papers (10378)
Page 99 of 173, ranked by citation count.
- Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment.
- Evaluation of gastric content in fasting patient during semaglutide use: an observational study.
- Exenatide regulates inflammation and the production of reactive oxygen species via inhibition of S1PR2 synthesis.
- Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue.
- Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus.
- Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.
- Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
- Exendin-4 impairs the autophagic flux to induce apoptosis in pancreatic acinar AR42J cells by down-regulating LAMP-2.
- Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.
- Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.
- Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.
- Exendin-4 modifies adipogenesis of human adipose-derived stromal cells isolated from omentum through multiple mechanisms.
- Oral GLP-1 Analog for Type 2 Diabetes on the Horizon.
- Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
- VMP1-related autophagy induced by a fructose-rich diet in β-cells: its prevention by incretins.
- Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.
- Microcosmic mechanism of dication for inhibiting acylation of acidic Peptide.
- Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.
- Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.
- Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.
- EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS.
- Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis.
- A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
- Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses.
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.
- Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.
- Glycosylation Improves the Proteolytic Stability of Exenatide.
- Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity
- The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
- The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-κB pathway.
- Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
- Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.
- Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
- Semaglutide Alleviates Ovarian Oxidative Stress and Autophagy via the PI3K/AKT/mTOR Pathway in Mice with Polycystic Ovary Syndrome.
- Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
- The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide.
- [Association between SORCS1 rs1416406 and therapeutic effect of exenatide].
- Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale.
- Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells.
- Central nervous system pathways targeted by amylin in the regulation of food intake.
- Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
- Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway.
- Glycaemic control with liraglutide: the phase 3 trial programme.
- Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.
- Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery.
- Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
- Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance.
- Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
- Tirzepatide-Related Acute Liver Injury.
- Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
- Albiglutide for the management of type 2 diabetes.
- New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
- Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells.
- Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis.
- Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.
- Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
- The first successful desensitization protocol in exenatide allergy: a case report.